PK/PD of Polymyxins Against Gram-Negative ?Superbugs?

Elizabeth D Hermsen,Christopher J Sullivan,John C Rotschafer

2013-01-01

Pharmaceutica Analytica Acta

Abstract:Monash University, Australia I multidrug-resistance in Gram-negative ‘superbugs’, in particular Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae, is presenting a global medical challenge. Th ere is no novel candidate in the antibiotic development pipeline for these ‘superbugs’ and no new anti-Gram-negative antibiotic will be clinically available at least in the next decade. Limited therapeutic options have forced infectious disease clinicians and microbiologists to reappraise the clinical application of polymyxins (i.e. colistin and polymyxin B), antibiotics discovered more than 60 years ago. Th is presentation summarizes recent progress in understanding of the complex pharmacokinetics and pharmacodynamics of colistin and polymyxin B, the interplay between these three aspects and their impact on the clinical use of these two important antibiotics. Recent clinical fi ndings are reviewed, focusing on evaluation of effi cacy, emerging resistance, potential toxicities and combination therapy. In the battle against rapidly emerging bacterial resistance we can no longer rely entirely on the discovery of new antibiotics; we must also pursue rational approaches to the use of older antibiotics such as polymyxins.